Comment on Rotshild et al’s “The Risk for Prostate Cancer With Calcium Channel Blockers”

Abstract

Get full access to this article

View all access options for this article.

References

Rotshild

Rabkin

Matok

The risk for prostate cancer with calcium channel blockers: a systematic review, meta-analysis, and meta-regression. Ann Pharmacother. 2023;57:16-28. doi:10.1177/10600280221098121

Yang

, et al. Association between the overall risk of prostate cancer and use of calcium channel blockers: a systematic review and meta-analysis. Clin Ther. 2020;42:1715-1727.e2. doi:10.1016/j.clinthera.2020.06.021

Cao

Zhang

Jia

, et al. Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies. BMC Urol. 2018;18:17. doi:10.1186/s12894-018-0318-7

Thakur

Wang

Garcia-Betancourt

Forse

. Calcium channel blockers and the incidence of breast and prostate cancer: a meta-analysis. J Clin Pharm Ther. 2018;43:519-529. doi:10.1111/jcpt.12673

Frishman

WH.

Calcium channel blockers: differences between subclasses. Am J Cardiovasc Drugs. 2007;7(suppl 1):17-23. doi:10.2165/00129784-200707001-00003

Elliott

Ram

CV.

Calcium channel blockers. J Clin Hypertens (Greenwich). 2011;13:687-689. doi:10.1111/j.1751-7176.2011.00513.x